ADCT Stock Summary and Trading Ideas (Adc Therapeutics SA Common Shares | NYSE:ADCT)

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.

Adc Therapeutics SA Common Shares trades on the NYSE stock market under the symbol ADCT.

As of May 6, 2024, ADCT stock price declined to $4.50 with 1,513,764 million shares trading.

ADCT has a beta of 1.50, meaning it tends to be more sensitive to market movements. ADCT has a correlation of 0.02 to the broad based SPY ETF.

ADCT has a market cap of $372.66 million. This is considered a Small Cap stock.

Last quarter Adc Therapeutics SA Common Shares reported $17 million in Revenue and -$.97 earnings per share. This beat revenue expectation by $1 million and missed earnings estimates by -$.47.

In the last 3 years, ADCT stock traded as high as $32.00 and as low as $.36.

ADCT has outperformed the market in the last year with a return of +135.6%, while the SPY ETF gained +28.0%. In the last 3 month period, ADCT beat the market returning +25.0%, while SPY returned +4.6%. However, in the most recent 2 weeks ADCT has underperformed the stock market by returning -4.7%, while SPY returned +4.1%.

ADCT support price is $4.62 and resistance is $5.18 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ADCT stock will trade within this expected range on the day.